Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

A minituarized disposable molecular diagnostics platform for combatting coronavirus infections

Project description

Novel diagnostic platform for COVID-19 rapid test

The EU-funded DECISION project is developing a new class of COVID-19 diagnostic platforms and tests in a joint effort by teams from Italy, Spain and Germany. The diagnostic platform will enable the rapid detection of COVID-19 infections on-site in any possible setting, including drive-through testing centres, airports or medical offices. The low-cost, miniature, disposable diagnostic platform is powered by a next-generation nucleic acid amplification technology called pulse controlled amplification (PCA®), providing sample-to-answer workflows in less than 15 minutes. The objective is to deliver the molecular diagnostic platform and coronavirus test within five months after the start of the project.

Objective

The DECISION consortium is developing a new class of diagnostic platform that will transform the fight against pandemics.

The low-cost, miniaturised, disposable molecular diagnostic platform will allow for patient testing virtually anywhere, within a few minutes, with laboratory quality performance. The diagnostic platform will enable rapid detection of Covid-19 infections on-site in a multitude of settings including drive-through testing centres, physician offices, airports, hospitals and quarantine centres.

First demonstrators of the disposable molecular diagnostic platform and coronavirus test will be available five months after the start of the project and could be provided to emergency first responders and public health authorities.

The platform is powered by a next-generation nucleic acid amplification technology called Pulse Controlled Amplification (PCA®), which enables sample-to-answer workflows in 15 minutes or less.

The DECISION consortium is comprised of teams from Italy, Spain and Germany, and is highly motivated to develop a ground-breaking diagnostic solution to help the serious crisis faced across the world due to the Covid-19 epidemic.

Coordinator

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH
Net EU contribution
€ 2 224 178,49
Address
GIEFINGGASSE 4
1210 Wien
Austria

See on map

Region
Ostösterreich Wien Wien
Activity type
Research Organisations
Links
Total cost
€ 2 224 178,49

Participants (4)